Achieve Life Sciences (ACHV) Enterprise Value (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Enterprise Value came in at -$30.5 million in Q1 2026, down 31.17% YoY from -$44.3 million in Q1 2025, and up 41.22% on a QoQ basis from -$51.9 million in Q4 2025.
Achieve Life Sciences (ACHV) Enterprise Value (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 17 years of Enterprise Value data on file, last reported at -$30.5 million in Q1 2026.
- Quarterly Enterprise Value fell 31.17% year-over-year to -$30.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$30.5 million (down 31.17% YoY) and the FY2025 annual result came in at -$51.9 million, down 50.97% from the prior year.
- Enterprise Value grew to -$30.5 million in Q1 2026, from -$51.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$14.3 million in Q4 2023 to a low of -$66.4 million in Q1 2024.
- A 5-year average of -$35.9 million and a median of -$30.5 million in 2026 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value sank 302.08% — and 2025, when it jumped 64.99%.
- Tracing ACHV's Enterprise Value over 5 years: stood at -$24.8 million in 2022, then soared by 42.46% to -$14.3 million in 2023, then plunged by 141.09% to -$34.4 million in 2024, then sank by 50.97% to -$51.9 million in 2025, then surged by 41.22% to -$30.5 million in 2026.
- The last three Enterprise Value figures came in at -$30.5 million (Q1 2026), -$51.9 million (Q4 2025), and -$64.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | -326.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -326.65 Mn |
| Mar 31, 2026 | -30.49 Mn |
| Dec 31, 2025 | -51.88 Mn |
| Sep 30, 2025 | -64.28 Mn |
| Jun 30, 2025 | -54.71 Mn |
| Mar 31, 2025 | -23.25 Mn |
| Dec 31, 2024 | -34.36 Mn |
| Sep 30, 2024 | -42.91 Mn |
| Jun 30, 2024 | -61.02 Mn |
| Mar 31, 2024 | -66.40 Mn |
| Dec 31, 2023 | -14.25 Mn |
| Sep 30, 2023 | -17.92 Mn |
| Jun 30, 2023 | -25.10 Mn |
| Mar 31, 2023 | -16.51 Mn |
| Dec 31, 2022 | -24.77 Mn |
| Sep 30, 2022 | -18.20 Mn |
| Jun 30, 2022 | -27.98 Mn |
| Mar 31, 2022 | -36.34 Mn |
| Dec 31, 2021 | -41.86 Mn |
| Sep 30, 2021 | -23.51 Mn |